CMS Will Weigh Three New Tech Assessments On Genetic Testing For Cancer
This article was originally published in The Pink Sheet Daily
Two of the assessments are intended to inform an upcoming Medicare Evidence Development and Coverage Advisory Committee meeting.
You may also be interested in...
The industry’s angst is growing several months after CMS announced a plan to task contractors with independently setting regional payments for more than 100 new molecular diagnostic codes. A breakdown in the process so far, stakeholders say, could have a lasting impact on small, venture-backed labs.
CMS includes genetic testing on its updated list of potential topics for Medicare national coverage determinations, released Nov. 27. But no biopharmaceuticals are on the list this time around.
The Agency for Healthcare Research and Quality has identified 38 new genetic tests for cancer that have entered U.S. or overseas markets since 2006, with breast cancer the most common disease target.